- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1945KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 773KB)
Nusinersen – July 2021
Nusinersen: Solution for injection 12.6 mg in 5 mL; Spinraza®
Last updated
29 October 2021